The draft guidance gives recommendations for reproductive toxicity testing and labeling.
On Sept. 28, 2017, FDA published draft guidance on reproductive toxicity testing and labeling of oncology pharmaceuticals. The guidance discusses embryo-fetal development (EFD) toxicity, results of genotoxicity and general toxicity studies, and labeling recommendations concerning EFD studies and the potential risk of adverse development outcomes.
Risks from biosimilar products, interchangeable products, radio-pharmaceuticals, cellular and gene therapy products, or cancer vaccines are not addressed in the guidance. It also does not discuss margins of safety by exposure or dose.
The FDA guidance complements International Council for Harmonization (ICH) guidance and provides examples of alternative assessments and additional recommendations not described in ICH guidelines.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.